Abstract
Obstructive sleep apnea (OSA) is a growing public health hazard fueled by the obesity epidemic and an aging population. Untreated sleep apnea can result in significant consequences both in the short-term and long-term. We need to educate the public to recognize the symptoms of sleep apnea and to publicize that effective treatments are available. Positive airway pressure therapy remains the gold standard currently in treating OSA. Alternative treatments include an oral appliance or surgical options. This paper discusses the pharmacologic treatment of sleep apnea: goals include medications to address the ventilatory control of breathing, treat co-morbid diseases, treat associated health problems/complaints, address special issues, such as anesthetic precautions, and propose future targets.
Keywords: Obstructive sleep apnea, treatment, pharmacotherapy, targets, CPAP, Obstructive, apnea, anesthetic, hypertension, retropharyngeal, Bariatric surgery, cholinergic, nasal congestion, acromegaly, theophylline, aminophylline, caffeine, methylxanthine, Naloxone, oxyhemoglobin
Current Pharmaceutical Design
Title: Pharmacological Treatment of Obstructive Sleep Apnea
Volume: 17 Issue: 15
Author(s): Vivien C. Abad and Christian Guilleminault
Affiliation:
Keywords: Obstructive sleep apnea, treatment, pharmacotherapy, targets, CPAP, Obstructive, apnea, anesthetic, hypertension, retropharyngeal, Bariatric surgery, cholinergic, nasal congestion, acromegaly, theophylline, aminophylline, caffeine, methylxanthine, Naloxone, oxyhemoglobin
Abstract: Obstructive sleep apnea (OSA) is a growing public health hazard fueled by the obesity epidemic and an aging population. Untreated sleep apnea can result in significant consequences both in the short-term and long-term. We need to educate the public to recognize the symptoms of sleep apnea and to publicize that effective treatments are available. Positive airway pressure therapy remains the gold standard currently in treating OSA. Alternative treatments include an oral appliance or surgical options. This paper discusses the pharmacologic treatment of sleep apnea: goals include medications to address the ventilatory control of breathing, treat co-morbid diseases, treat associated health problems/complaints, address special issues, such as anesthetic precautions, and propose future targets.
Export Options
About this article
Cite this article as:
C. Abad Vivien and Guilleminault Christian, Pharmacological Treatment of Obstructive Sleep Apnea, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197106
DOI https://dx.doi.org/10.2174/138161211796197106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Flavonoids, Vascular Function and Cardiovascular Protection
Current Pharmaceutical Design Aβ Monomers, Oligomers and Fibrils: Structural Features
Current Bioactive Compounds Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Myeloperoxidase: The Good, the Bad, and the Ugly
Current Immunology Reviews (Discontinued) Cardiovascular Imaging in Thromboembolic Risk Stratification for Atrial Fibrillation: Recent Patents and Current Practice
Recent Patents on Medical Imaging Colchicine: A Review on Chemical Structure and Clinical Usage
Infectious Disorders - Drug Targets Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?
Current Vascular Pharmacology Involvement of P-glycoprotein and Multidrug Resistance Associated Protein 1 in the Transport of Tanshinone IIB, a Primary Active Diterpenoid Quinone from the Roots of Salvia miltiorrhiza, Across the Blood-Brain Barrier
Drug Metabolism Letters Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology